DEC1 Polyclonal antibody
DEC1 Polyclonal Antibody for IHC, ELISA
Host / Isotype
Rabbit / IgG
Reactivity
human and More (1)
Applications
WB, IHC, ELISA
Conjugate
Unconjugated
Cat no : 25021-1-AP
Synonyms
Validation Data Gallery
Tested Applications
Positive IHC detected in | human prostate cancer tissue, human testis tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
Recommended dilution
Application | Dilution |
---|---|
Immunohistochemistry (IHC) | IHC : 1:50-1:500 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
Published Applications
WB | See 1 publications below |
Product Information
The immunogen of 25021-1-AP is DEC1 Fusion Protein expressed in E. coli.
Tested Reactivity | human |
Cited Reactivity | rat |
Host / Isotype | Rabbit / IgG |
Class | Polyclonal |
Type | Antibody |
Immunogen | DEC1 fusion protein Ag20192 |
Full Name | deleted in esophageal cancer 1 |
Calculated Molecular Weight | 70 aa, 8 kDa |
GenBank Accession Number | BC153139 |
Gene Symbol | DEC1 |
Gene ID (NCBI) | 50514 |
RRID | AB_2879851 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Antigen affinity purification |
Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
DEC1 (Deleted in esophageal cancer 1), also named as CTS9 (Candidate tumor suppressor CTS9),is a tumor suppressor protein. It is expressed in many tissues, with highest expression in prostate and testis. This gene is different to another DEC1 protein (Differentially expressed in chondrocytes protein 1, BHLHE40).
Protocols
Product Specific Protocols | |
---|---|
IHC protocol for DEC1 antibody 25021-1-AP | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |
Publications
Species | Application | Title |
---|---|---|
FASEB J Persistent myopathy despite release of partial obstruction: in vivo reversal of dysfunction and transcriptional responses using rapamycin. |